Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma

Further research on selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma in the form of prospective studies, including randomised controlled trials, should address patient selection, quality-of-life outcomes and overall survival. Patient selection for the research studies should be done by a
multidisciplinary team. The procedure should only be done in specialist centres by clinicians trained and experienced in managing cholangiocarcinoma.

Clinicians should enter details about all patients having selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma onto a suitable registry.